Frontlight ResearchEarly access
Myelodysplastic syndromes trials in United States
224 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- No phaseEnrolling by invitationBiology Studies of Hematologic Cancers
- Where
- Bethesda
- Age
- 1 year to 120 years
- People
- 550
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT00923442 - Phase 1Taking peopleCER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)
- Where
- Denver, Houston, Nashville, Sacramento, Seattle
- Age
- 18 years to 85 years
- People
- 18
- Run by
- CERo Therapeutics Holdings, Inc.
See details and how to joinNCT06834282 - Phase 1Taking peopleTherapeutic RSK1 Targeting in Myeloid Malignancies
- Where
- St Louis
- Age
- 18 years and over
- People
- 30
- Run by
- Washington University School of Medicine
See details and how to joinNCT07379125 - Phase 2Taking peopleGraft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
- Where
- Pittsburgh, Seattle, Tampa
- Age
- 1 year to 60 years
- People
- 120
- Run by
- Fred Hutchinson Cancer Center
See details and how to joinNCT03970096 - Phase 1Taking peopleEganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS
- Where
- Aurora, Boston, Cleveland, Columbus, Duarte, Houston, New York, St Louis, Tampa
- Age
- 18 years and over
- People
- 105 worldwide
- Run by
- Stelexis BioSciences
See details and how to joinNCT06533761 · EU 2024-518071-58-00 - Phase 1Taking peopleOlutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
- Where
- Cleveland, Duarte
- Age
- 18 years and over
- People
- 15
- Run by
- City of Hope Medical Center
See details and how to joinNCT06543381 - Phase 2Taking peopleInduction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
- Where
- Portland
- Age
- 18 years to 65 years
- People
- 102
- Run by
- OHSU Knight Cancer Institute
See details and how to joinNCT07228273 - Phase 1Taking peopleCD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML
- Where
- Aurora
- Age
- 18 years and over
- People
- 23
- Run by
- University of Colorado, Denver
See details and how to joinNCT07347418 - Phase 2Taking peopleA Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
- Where
- Bethesda, Duarte, Hackensack, Hot Springs, Houston, Lansing, Memphis, Miami, Pittsburgh, Shirley, Tampa
- Age
- 18 years and over
- People
- 210 worldwide
- Run by
- Takeda
See details and how to joinNCT04419649 · EU 2023-507469-24-00 - Phase 2Taking peopleRuxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
- Where
- Seattle
- Age
- 18 years to 75 years
- People
- 50
- Run by
- Fred Hutchinson Cancer Center
See details and how to joinNCT07228624 - Phase 2Taking peopleAllogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations
- Where
- Bethesda
- Age
- 6 years to 70 years
- People
- 144
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT01861106 - Phase 2Taking peopleA Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
- Where
- Bethesda
- Age
- 18 years to 75 years
- People
- 54
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT05027945 - No phaseTaking peopleComprehensive Molecular and Clinical Evaluation of Pediatric and Adult MDS
- Where
- Bethesda
- Age
- 1 day to 120 years
- People
- 1,100
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT05350748 - No phaseTaking peopleLeukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care
- Where
- Chicago, Miami, San Antonio
- Age
- 18 years and over
- People
- 400
- Run by
- University of Miami
See details and how to joinNCT05745285 - Phase 2Taking peopleA Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
- Where
- Boston, Cleveland, Columbus, Houston, New York, Rochester, Salt Lake City, Scottsdale, Seattle
- Age
- 18 years and over
- People
- 156 worldwide
- Run by
- Swedish Orphan Biovitrum
See details and how to joinNCT06782373 · EU 2024-516347-41-00 - Phase 1Taking peoplePhase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- Where
- Buffalo, Chapel Hill, Columbus, Duarte, Houston, Nashville, New York, Philadelphia, Tampa
- Age
- 18 years and over
- People
- 69 worldwide
- Run by
- Auron Therapeutics, Inc.
See details and how to joinNCT06846606 · EU 2025-521394-13-00 - No phaseTaking peopleStudy of Individuals and Families With Aberrations in DDX41 or Similar Cancer Predisposition Variants
- Where
- Bethesda
- Age
- 1 month to 120 years
- People
- 510
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT07019155 - No phaseEnrolling by invitationForecasting Relapse Outcomes With AlloHeme-based Risk Detection in Post-Allo-HCT AML/MDS Patients (FORWARD)
- Where
- Brisbane, San Francisco, St Louis
- Age
- 18 years and over
- People
- 400
- Run by
- CareDx
See details and how to joinNCT07607327 - Phase 1Taking peopleDanvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML
- Where
- Houston, The Bronx
- Age
- 18 years and over
- People
- 38
- Run by
- Montefiore Medical Center
See details and how to joinNCT05986240 - Phase 2Taking peopleEffects of IL-1 Beta Inhibition on Vascular Inflammation in TET2 Clonal Hematopoiesis
- Where
- Boston
- Age
- 18 years and over
- People
- 120
- Run by
- Massachusetts General Hospital
See details and how to joinNCT06691217 - No phaseEnrolling by invitationMolecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study
- Where
- Bethesda
- Age
- 2 years to 120 years
- People
- 1,400
- Run by
- National Heart, Lung, and Blood Institute (NHLBI)
See details and how to joinNCT07102849 - Phase 2Taking peopleRuxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
- Where
- Duarte
- Age
- 2 years to 22 years
- People
- 40
- Run by
- City of Hope Medical Center
See details and how to joinNCT06128070 - No phaseTaking peopleWhole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in MDS
- Where
- St Louis
- Age
- 18 years and over
- People
- 100
- Run by
- Washington University School of Medicine
See details and how to joinNCT05434598 - No phaseNot yet taking people in United StatesCD34+ Enriched Transplants to Treat Myelodysplastic Syndrome
- Where
- Miami
- Age
- 18 years to 72 years
- People
- 62
- Run by
- Guenther Koehne
See details and how to joinNCT05617625 - Phase 3Taking peopleLisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
- Where
- Aurora, Austin, Baltimore, Birmingham, Charlotte, Charlottesville, Chicago, Cleveland, Columbus, Durham, Edmonds, Eugene, Hackensack, Houston, Indianapolis, Iowa City, Issaquah, Jacksonville, Lincoln, Los Angeles, Louisville, Manassas, Milwaukee, Minneapolis, New York, Norfolk, Phoenix, Pittsburgh, Providence, Rochester, Sacramento, San Diego, Seattle, St Louis, The Bronx, Tyler, Waukesha, Winston-Salem
- Age
- 18 years and over
- People
- 490 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06641414 · EU 2024-517247-31-00